Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 06:02 AM. | Search:

» StockRants Stock Forum » Public Stock Forums » Canadian Stock Picks » Strong Buy: CPE.H - Capital Pro Egaux Inc.



Reply
 
Thread Tools Search this Thread
Old 10-24-2016, 12:51 PM   Nav to Top  #1
JonnyR512
Senior Trader
 
JonnyR512's Avatar
 
Join Date: Jul 2009
Location: N/A
Posts: 1,338
Favorites: AXM, KUB
Rep Power: 184
Reputation: 168
JonnyR512 has a spectacular aura aboutJonnyR512 has a spectacular aura about
Default CPE.H - Capital Pro Egaux Inc.

Capital Pro-Egaux Inc. Due Diligence Report

Company Overview: Pro-Égaux and its wholly-owned subsidiary, Technique d’Usinage Sinlab Inc. (“Sinlab”), specialize in the licensing of titanium products for the dental implant prosthetics restoration market.

Price: $0.20
Common Shares: 4,195,077
Insider Holdings: 1,636,309 (39% as per the last information circular filed this year)
Options: 419,508 exercisable at $0.10

Financials
Note: Most liabilities mentioned are “deferred revenue” which is actually revenue received, but cannot be posted as income yet. See definition: http://www.accountingcoach.com/blog/deferred-revenue

Assets
Cash: $342,289
Accounts Receivable: $28,839
Advance to a shareholder: $18,000
Prepaid Expenses: $1,564
Intangible Assets: $42,553
Total Assets: $433,245

Liabilities
Payables: $130,881
Deferred revenue(current): $695,479
Promissory Note: $670,747
Deferred Revenue(non current):$231,826
Total Liabilities: $1,728,933

2017 Income Statement(6 Months)
Revenue: $533,207
Net Income: $266,998 or $0.064 earnings per share

2016 Yearly Income Statement(Audited Annual)
Revenue: $1,393,669
Net Income: $706,595 or $0.17 earnings per shares

2014 Yearly Income Statement(Audited Annual)
Revenue: $747,677
Net Income: $237,922 or $0.057 earnings per shares

Capital Pro MD&A Highlights from most recent Quarter(ending August 31 2016)
Note: The MD&A on Sedar is very long, this is a strictly highlights.

During the first and second quarters of fiscal 2017, the Company main activities were related to the follow up of the malpractice lawsuit as described in the next section of this MD&A. Also the Company concentrates its effort on pursuing smaller but numerous potential counterfeiters in all countries where our various patents have been validated by the signed licenses.

During the second quarter of fiscal 2017, the Company signed two new licence Agreements. On June 29th, 2016, the subsidiary of the Company, Sinlab entered into a Patent License Agreement with Cybermed Inc. (“Cybermed”). As part of the agreement, Sinlab granted Cybermed and all resellers and users of Cybermed products, a worldwide, irrevocable, non-exclusive, fully paid up, royalty free and transferable license to make, use, sell and offer to sell the inventions of the Guide Patent in the portfolio through Cybermed products and services. The terms and conditions of the Agreement are undisclosed for confidentiality reasons.

Also on August 5th, 2016 the subsidiary of the Company, Sinlab signed a Patent License Agreement with James R. Glidewell Dental Ceramic Inc. (“Glidewell”). Under this agreement, Sinlab granted Glidewell and its affiliates and all resellers and users of Glidewell’s and its affiliates’ products and services worldwide irrevocable, non-exclusive, fully paid up, royalty free and transferable license to make, use, sell, offer to sell and import to United States the inventions of the Licensed Portfolio. The term of these licenses are for the life of the last expiring Patent in the Licensed Portfolio. The terms and conditions of the Agreement are undisclosed for confidentiality reasons. Many other potential agreements are still under discussion as of the date of this MD&A.

As of the date of approval of this MD&A on October 21th, 2016 by the board of directors, the status of the various court actions for the protection of our patents has been summarized to reflect the final result of all of our past court actions ending with the yearly MD&A dated February 29th , 2016 and February 28th, 2015 respectively. Only the current activity is covered in the following Current Court Action section:

Further to a Board of Directors’ resolution dated December 15th, 2013, the Company announced, on December 20th, 2013, that its wholly owned subsidiary, Sinlab, has filed an action for damages it believes are the result of professional malpractice of certain former legal counsels of Sinlab in connection with matters pertaining to the announced settlements involving Delcam USA, Inc. and Delcam Holdings, Inc., Cagenix, Inc., Dentsply International Inc. and the Nobel Entities, comprised of Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc.; Biocad Médical Inc.; Nobel Biocare USA, LLC; and Nobel Biocare Procera, LLC.

As of the date of approval of this MD&A on October 21th, 2016, the above filed action, for damages we believes are the result of professional malpractice of certain former legal counsels of Sinlab, is proceeding as follows with very little activity in this quarter:
· Initial exchange of discovery documents completed; document discovery ongoing;
· Written discoveries still ongoing and to date, all request were answered by Sinlab Inc;
· Discovery dispute concerning Nobel confidential information has been resolved in the first quarter of fiscal 2015;
· Oral discovery (Deposition) started in February 2016 and most likely to complete by end of August/ September 2016;
· Experts for most areas have been identified and expert discovery expected to be scheduled for hearing by Court Authorities in last quarter of 2016 or, most likely, in the first half of year 2017;
· The court has placed the case in the complex litigation division;
· Defendants Murphy & King and Smith Gambrel Russel have filed counterclaims for their fees from the underlying action plus interest. Defendant SGR served a “Rule 57.105" motion arguing that the case against it is baseless. If they are successful, Sinlab would be liable for their attorneys’ fees in this action from 30 days after the date of the service. For many reasons, Sinlab considers the defendant success on the motion to be unlikely, and their claims for fees unlikely to be successful.
· Court Authorities will be placing our case on their schedule of court hearing sessions. It is expected to be sometime before the month of June 2017.
JonnyR512 is offline   Rate this post Yes | No Reply With Quote
Old 01-11-2017, 09:51 AM   Nav to Top  #2
JonnyR512
Senior Trader
 
JonnyR512's Avatar
 
Join Date: Jul 2009
Location: N/A
Posts: 1,338
Favorites: AXM, KUB
Rep Power: 184
Reputation: 168
JonnyR512 has a spectacular aura aboutJonnyR512 has a spectacular aura about
Thread Starter
Default

Capital Pro-Egaux licenses patents to nSequence et al.



2017-01-10 09:21 MT - News Release


Mr. Pierre Desormeau reports

CAPITAL PRO-EGAUX INC. (NEX: CPE.H) ANNOUNCES THE CONCLUSION OF A LICENSE AGREEMENT WITH NSEQUENCE CENTER FOR ADVANCED DENTISTRY AND NATIONAL DENTEX CORPORATION

Capital Pro-Egaux Inc.'s wholly owned subsidiary, Technique d'usinage Sinlab Inc., has entered into a patent licence agreement with nSequence Center for Advanced Dentistry and National Dentex Corp. As part of the agreement, Sinlab granted licensees a non-exclusive worldwide licence to make, use, sell and offer to sell inventions covered by its patents, including patents relating to its Technobar and Technoguide technologies, under terms undisclosed for confidentiality reasons.

Unlicensed entities should obtain an appropriate licence from Sinlab by contacting M. Jean Kingsley via e-mail.

The company previously announced settlement and/or licence agreements that include Biomet 3i LLC (formerly Implant Innovations Inc.), Delcam USA Inc. and Delcam Holdings Inc., Cagenix Inc., Dentsply International Inc., Nobel Biocare AB, Nobel Biocare Italiana SRL, Nobel Biocare Holding AG, Nobel Biocare Deutschland GmbH, Nobel Biocare Canada Inc., Biocad Medical Inc., Nobel Biocare USA LLC, Nobel Biocare Procera LLC, 3Shape A/S, exocad America Inc., MIS Implants Technologies Ltd., SICAT Gmbh & Co. KG, and James R. Glidewell Dental Ceramics Inc. The company is currently pursuing its licensing program with other industry participants. The company cannot predict the outcome of its continuing negotiations or of any legal proceedings it may decide to institute against those entities that fail or refuse to contract a licence. The decision to take legal proceedings will be based on available information and the company's assessment of all relevant facts and circumstances, including costs involved with such proceedings. Such costs are unpredictable and may be substantial.

We seek Safe Harbor.

© 2017 Canjex Publishing Ltd. All rights reserved.
JonnyR512 is offline   Rate this post Yes | No Reply With Quote
Old 01-25-2017, 02:00 PM   Nav to Top  #3
JonnyR512
Senior Trader
 
JonnyR512's Avatar
 
Join Date: Jul 2009
Location: N/A
Posts: 1,338
Favorites: AXM, KUB
Rep Power: 184
Reputation: 168
JonnyR512 has a spectacular aura aboutJonnyR512 has a spectacular aura about
Thread Starter
Default

Capital Pro-Egaux Inc. Quarterly Results

Price: $0.10
Common Shares: 4,195,077
Insider Holdings: 1,636,309 (39% as per the last information circular filed this year)
Options: 419,508 exercisable at $0.10

Assets
Cash: $319,939
Accounts Receivable: $29,892
Advance to shareholder: $18,000
Prepaid Expenses: $2,082
Intangible Assets: $34,574
Total Assets: $404,487

Liabilities
Accounts Payable: $164,339
Deferred Revenue: $695,479
Current Portion Deferred Revenue: $57,956
Promissory Note: $720,569
Total Liabilities: $1,638,343

Note: Deferred revenue will disappear over time. Lawsuit against various parties has commenced. See MD&A highlights below.

Revenue after 9 months
Licensing & Royalties: $723,846
Net Income: $328,830 or $0.078

MD&A Highlights
As of the date of approval of this MD&A on January 25th, 2017, the above filed action, for damages we believes are the result of professional malpractice of certain former legal counsels of Sinlab, is proceeding as per the formal Scheduling Order issued by the Hon Judge Tuter on November 18th, 2016:
• Expert disclosures by plaintiff of their opening experts to be completed by January, 10th , 2017.
• Defendants shall disclose their experts by February 24th, 2017.
• Expert deposition schedule shall take place between March 31st, 2017 and June 30th, 2017.
• Discovery deadlines: Parties shall complete all fact discoveries by March 31st, 2017. All expert discoveries by June 30th, 2017.
• Trial Witnesses: The parties shall disclose all “Trial Witnesses” (excluding experts) by August 31st, 2017.
• Trial Exhibits: The parties shall disclose all exhibits to be used at trial by August, 31st , 2017 The remaining of the Scheduling Order will be posted in our Q 4 (February 2017) end of year Management report.

During all quarters of fiscal 2017, the Company main activities were related to the follow up of the malpractice lawsuit as described in the next section of this MD&A. Also the Company concentrates its effort on pursuing smaller but numerous potential counterfeiters in all countries where our various patents have been validated by the signed licenses.

The positive resolution with 3i, the agreements signed with many patent infringers may enable us to extend license to end of patent life thus, ensuring minimum revenues. Cash flow will be used for conducting litigations in relation with the Technobar patent against small other infringers and potentially generate an additional revenue stream to our shareholders.

On December 15th, 2016, the subsidiary of the Company, Sinlab entered into a Patent License Agreement with Nsequence for Advance Dentistry (“Nsequence”) and National Dental Corporation (“National Dental”). As part of the agreement, Sinlab granted Nsequence and National Dental a worldwide, irrevocable, non-exclusive, fully paid up, royalty free and transferable license to make, use, sell and offer to sell the inventions of the Guide and Superstructure Patents in the portfolio through Licensee’s products and services that were offered commercially on or after the Effective Date. The terms and conditions of the Agreement are undisclosed for confidentiality reasons.

Business Strategy
Other than managing our malpractice action for damages we believe are the result of professional malpractice of certain former legal counsels of Sinlab, the company main focus and strategy, now that licenses have been signed with Nobel, Dentsply, Cagenix and many others, is to concentrate on pursuing the smaller but numerous potential counterfeiters in all countries where our various patents have been validated by the signed licenses.
As of January 25th, 2017 the situation is as follows:
• Patent and technology surveillance has demonstrated that, we believe, various companies have and are building their businesses along the same claim references of our patents;
• Amicable letters, from our President, proposing licensing arrangements have been forwarded to various companies on August 16th, 2014 and, to date, we have received contact feed-back from 6 companies and discussions are in progress;
• Follow up letters has been forwarded on August 26th, 2014 to the others to remind them that we have a history of respecting the intellectual property of others and a history for protection Sinlab’s intellectual property rights for the benefit of the shareholders of our public parent company, Capital Pro Égaux Inc.;
• The Company has entered into licensing discussions with various players in Europe as well as America. Due to the confidential nature of the discussions, update of the discussions will be published once all negotiations are completed;
• As reported in the “ Company Revenue stream” section, three additional licenses have been executed in the last 8 months
• The Company expects to conclude a minimum of 2 additional licenses in its next 6 months
The Company is actively looking for opportunities to conclude a business association that will create added value to our shareholders. Various business plans are being evaluated with the objective of executing a business agreement that will maximize our PUBLIC COMPANY value. Should the Company enter into such an agreement, a letter of intent will be duly signed and, a Press Release will be issued accordingly.
JonnyR512 is offline   Rate this post Yes | No Reply With Quote
Old 03-12-2019, 10:08 AM   Nav to Top  #4
JonnyR512
Senior Trader
 
JonnyR512's Avatar
 
Join Date: Jul 2009
Location: N/A
Posts: 1,338
Favorites: AXM, KUB
Rep Power: 184
Reputation: 168
JonnyR512 has a spectacular aura aboutJonnyR512 has a spectacular aura about
Thread Starter
Default

Capital Pro-Égaux Inc. (NEX: CPE.H) Announces Litigation Funding Agreement
Canada NewsWire

MORIN-HEIGHTS, QC, March 12, 2019

MORIN-HEIGHTS, QC, March 12, 2019 /CNW Telbec/ - Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a Litigation Funding Agreement for the funding of expenses related to the professional negligence action for damages commenced in 2013 in Florida against Sinlab's counsel who represented Sinlab in litigation in Virginia against certain entities who violated Sinlab's pioneering digital dentistry patent portfolio (the "Litigation").

Update on Litigation

The Litigation continues and is expected to be on the trial docket for the fourth quarter, 2019, with limited additional discovery during the next few months. To date, no defendant has offered any settlement payment to Sinlab.

Litigation Funding Agreement

The Company and Sinlab explored solutions to finance expenses relating to the Litigation, including a temporary revocation of the cease trade order to complete a private placement of common shares and funding from commercial litigation financing entities.

Ultimately, Sinlab entered into a litigation funding agreement with certain of its directors and officers upon terms and conditions consistent with those available from commercial litigation financing entities. The agreement provides for funding of litigation expenses in exchange for the payment of a portion of the proceeds from the resolution of the Litigation, including a settlement or a judgement, ranging between 20% and 40% depending on the amount of funding expended and timing of the resolution of the Litigation. In order not to hurt Sinlab's position in the Litigation, the amount of the funding is not disclosed. However, this amount is in the range of half a million dollars. Although the transaction constitutes a related party transaction of the Company within the meaning of applicable securities legislation, the Company is relying on certain exemptions from the formal valuation and minority approval requirements contained in such legislation.

"The principals of the Company are committed to seeing this Litigation through and are open to considering further financing if necessary" said Mr. Pierre Désormeau, president of the Company.

Caution regarding forward-looking statements

This news release contains certain forward-looking statements regarding the Company's expectation of future events, including potential claims and developments regarding legal proceedings. Such expectations are based on certain assumptions based on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could lead actual results to differ include, amongst others, factors that may impact claims and legal proceedings, such as interpretation of factual matters, time and money involved in undertaking legal proceedings, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by securities laws.

About Pro-Égaux Inc.

Pro-Égaux through its wholly owned subsidiary, Technique d'usinage Sinlab Inc., is a company based in Lachenaie, Quebec, specializing mainly in the conception and design of titanium products to be used in the dental prosthesis restoration industry.

Neither NEX, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of NEX and the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



SOURCE Capital Pro-Égaux Inc.

View original content: http://www.newswire.ca/en/releases/a.../12/c5339.html

Contact:

about this Press Release: Capital Pro-Égaux Inc., Pierre Désormeau, President, pdesormeau8007@gmail.com
JonnyR512 is offline   Rate this post Yes | No Reply With Quote
Reply

Tags
eps, healthcare, junior, Profitable, tsx, venture

Similar Threads
Thread Thread Starter Forum Replies Last Post
Long: XL - XL Capital Ltd. noiz6543 US Stock Picks 3 01-08-2010 07:08 PM
Watch: PNP.T Pinetree Capital splitmind Canadian Stock Picks 3 11-14-2009 12:06 PM
Buy: AHR - Anthracite Capital Inc. likesmoney US Penny Stock Picks 1 10-14-2009 11:32 AM
CAPITAL GAINS TAX shabiha Traders Lounge 53 10-11-2009 08:14 AM
AHR - Anthracite Capital rick002 Rumors & News 0 05-11-2009 07:30 PM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On